RxDoctor Payments DataLook up a doctor →

Brooke Brander, DO

Hematology & Oncology · Fayetteville, ARNPI 1083838239

Payments from drug & device makers

$6,180in general payments, 2019–2025

Across 373 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$835
  • AstraZeneca$413
  • Daiichi Sankyo Inc.$399
  • Novartis$389
  • Merck$369
  • Sanofi$287
  • plus $3K from 54 others

What the payments were for

  • Food & beverage$5,97497%
  • Education$2053%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)44$835
AstraZeneca19$413
Daiichi Sankyo Inc.25$399
Novartis20$389
Merck22$369
Sanofi20$287
Gilead(2 entities)12$284
Amgen22$280
Pfizer8$233
Eisai Inc.16$214
Takeda Pharmaceuticals U.S.A., Inc.13$201
Puma Biotechnology, Inc.13$191
Astellas Pharma US Inc10$155
GSK8$122
Rigel Pharmaceuticals, Inc.9$120
Blueprint Medicines Corporation6$105
Iovance Biotherapeutics, Inc.6$92
Bristol Myers Squibb6$85
Kyowa Kirin, Inc.6$84
Regeneron Healthcare Solutions, Inc.5$67
ADC Therapeutics America, Inc.4$62
Ipsen Biopharmaceuticals, Inc4$60
E.r. Squibb & Sons, L.L.C.4$57
Sobi, Inc4$57
Incyte Corporation4$53
Jazz Pharmaceuticals Inc.4$52
Sumitomo Pharma America, Inc.2$51
Seagen Inc.3$48
AbbVie3$45
Genentech USA, Inc.3$45
Bayer3$43
Stemline Therapeutics Inc.3$42
Beigene USA, Inc.3$42
Pharmacyclics LLC, An Abbvie Company2$38
EMD Serono, Inc.3$37
Tesaro, Inc.2$37
Menarini Silicon Biosystems, Inc.1$36
Recordati_rare_diseases_inc.2$36
Genmab U.S., Inc.2$35
Blue Earth Diagnostics2$31
Taiho Oncology, Inc.2$28
Morphosys, US Inc.2$26
Helsinn Therapeutics (U.S.), Inc.1$20
Geron Corporation1$19
Pharmacosmos Therapeutics Inc.1$18
Pharmaessentia USA Corporation1$18
Sanofi-aventis U.S. LLC1$18
Tersera Therapeutics LLC1$15
Foundation Medicine, Inc.1$14
Acceleron Pharma, Inc.1$14
Fennec Pharmaceuticals, Inc.1$14
Springworks Therapeutics, Inc.1$13
Epizyme, Inc.1$13
Exelixis Inc.1$13
Servier Pharmaceuticals LLC1$13
AVEO Pharmaceuticals, Inc.1$12
Karyopharm Therapeutics Inc.1$12
Alnylam Pharmaceuticals Inc.1$12
Array Biopharma Inc1$12
Dova Pharmaceuticals1$11

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,180 in reported general payments places this provider in the 40th percentile of 92 hematology & oncology providers in Arkansas.

See all hematology & oncology providers in Arkansas

Medicare billing

Part B allowed, 2024
$4,233,113
Medicare patients
1,418
Services billed
204,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JakafiRuxolitinib Phosphate38$670,804
IbrancePalbociclib33$510,290
ImbruvicaIbrutinib23$395,676
KisqaliRibociclib Succinate17$286,910
BrukinsaZanubrutinib17$218,766
VerzenioAbemaciclib14$202,739
XareltoRivaroxaban43$25,200
EliquisApixaban22$14,140
Abiraterone Acetate11$4,417
Exemestane44$3,781
Letrozole258$3,506
Anastrozole207$2,910
Tamoxifen Citrate86$1,853
Potassium Chloride95$1,563
Hydroxyurea47$1,190

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Incyte CorporationJakafi$53$670,80438 claims
PfizerIbrance, Eliquis$233$524,43155 claims
Pharmacyclics LLC, An Abbvie CompanyImbruvica$38$395,67623 claims
NovartisKisqali$389$286,91017 claims
Beigene USA, Inc.Brukinsa$42$218,76617 claims
Johnson & JohnsonXarelto$835$25,20043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 92 hematology & oncology providers in Arkansas.

Other hematology & oncology in Fayetteville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →